Abstract:Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and second leading cause of cancer-related deaths worldwide. The heightened mortality associated with HCC is largely attributed to its propensity for metastasis, which cannot be achieved without remodeling or loss of the basement membrane (BM). Despite advancements in targeted therapies and immunotherapies, resistance and limited efficacy in late-stage HCC underscore the urgent need for better therapeutic options and early diagnostic biomarkers. Our study aimed to address these gaps by investigating and evaluating potential biomarkers to improve survival outcomes and treatment efficacy in patients with HCC. Method: In this study, we collected the transcriptome sequencing, clinical, and mutation data of 424 patients with HCC from The Cancer Genome Atlas (TCGA) and 240 from the International Cancer Genome Consortium (ICGC) databases. We then constructed and validated a prognostic model based on metastasis and basement membrane-related genes (MBRGs) using univariate and multivariate Cox regression analyses. Five immune-related algorithms (CIBERSORT, QUANTISEQ, MCP counter, ssGSEA, and TIMER) were then utilized to examine the immune landscape and activity across high- and low-risk groups. We also analyzed Tumor Mutation Burden (TMB) values, Tumor Immune Dysfunction and Exclusion (TIDE) scores, mutation frequency, and immune checkpoint gene expression to evaluate immune treatment sensitivity. We analyzed integrin subunit alpha 3 (ITGA3) expression in HCC by performing single-cell RNA sequencing (scRNA-seq) analysis using the TISCH 2.0 database. Lastly, wound healing and transwell assays were conducted to elucidate the role of ITGA3 in tumor metastasis. Results: Patients with HCC were categorized into high- and low-risk groups based on the median values, with higher risk scores indicating worse overall survival. Five immune-related algorithms revealed that the abundance of immune cells, particularly T cells, was greater in the high-risk group than in the low-risk group. The high-risk group also exhibited a higher TMB value, mutation frequency, and immune checkpoint gene expression and a lower tumor TIDE score, suggesting the potential for better immunotherapy outcomes. Additionally, scRNA-seq analysis revealed higher ITGA3 expression in tumor cells compared with normal hepatocytes. Wound healing scratch and transwell cell migration assays revealed that overexpression of the MBRG ITGA3 enhanced migration of HCC HepG2 cells. Conclusion: This study established a direct molecular correlation between metastasis and BM, encompassing clinical features, tumor microenvironment, and immune response, thereby offering valuable insights for predicting clinical outcomes and immunotherapy responses in HCC.

Coupled scRNA-seq and Bulk-seq reveal the role of HMMR in hepatocellular carcinoma

Mir-9-5p/hmmr Regulates the Tumorigenesis and Progression of Clear Cell Renal Cell Carcinoma Through EMT and JAK1/STAT1 Signaling Pathway

Significance of HMMR Overexpression in Hepatocellular Carcinoma

Single-cell transcriptomics reveals tumor microenvironment changes and prognostic gene signatures in hepatocellular carcinoma

Identification of a novel circRNA-miRNA-mRNA regulatory axis in hepatocellular carcinoma based on bioinformatics analysis

RNA-seq profiling reveals PBMC RNA as a potential biomarker for hepatocellular carcinoma

High Expression of Hyaluronan-Mediated Motility Receptor Predicts Adverse Outcomes: A Potential Therapeutic Target for Head and Neck Squamous Cell Carcinoma.

Unveiling efferocytosis-related signatures through the integration of single-cell analysis and machine learning: a predictive framework for prognosis and immunotherapy response in hepatocellular carcinoma

Multilayered insights: a machine learning approach for personalized prognostic assessment in hepatocellular carcinoma

Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment

Single-cell transcriptome analysis reveals the metabolic changes and the prognostic value of malignant hepatocyte subpopulations and predict new therapeutic agents for hepatocellular carcinoma

Integrated single-cell and bulk RNA sequencing analysis revealing the role of FCGR2A on prognosis and immune infiltration of hepatocellular carcinoma

Analysis on Heterogeneity of Hepatocellular Carcinoma Immune Cells and a Molecular Risk Model by Integration of Scrna-Seq and Bulk RNA-seq

The Role of the Mitochondrial Ribosomal Protein Family in Detecting Hepatocellular Carcinoma and Predicting Prognosis, Immune Features, and Drug Sensitivity.

Construction of a lipid metabolism-related risk model for hepatocellular carcinoma by single cell and machine learning analysis

High Expression of RRM1 Mediated by Ncrnas Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma

Identification and characterization of RAC1-related immune and prognostic subtypes of hepatocellular carcinoma

HMMR triggers immune evasion of hepatocellular carcinoma by inactivation of phagocyte killing

Comprehensive molecular analyses of a 7-m6A-related lncRNAs signature for prognosis, tumor immunity and therapeutic effect in patients with hepatocellular carcinoma

Genomic analysis reveals RhoC as a potential marker in hepatocellular carcinoma with poor prognosis

Basement Membrane-Related Regulators for Prediction of Prognoses and Responses to Diverse Therapies in Hepatocellular Carcinoma